InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Public ClinicalTrials.gov record NCT05463796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer
Study identification
- NCT ID
- NCT05463796
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Enrollment
- 5,000 participants
Conditions and interventions
Conditions
- Adenomatous Hyperplasia
- Adult Cancer Survivors
- Barrett Esophagus
- Benign Bone Lesions With Risk of Malignant Degeneration
- Cancer Predisposition Syndrome
- Cancer Risk
- Cervical and Endocervical Carcinoma in Situ
- Childhood Cancer Survivors
- Cirrhosis
- Colonic Dysplasia/Adenomata
- Ductal/Lobular Carcinoma
- Endometrial Intraepithelial Neoplasia
- Giant Cell Tumor
- Hematologic Malignancy
- Hereditary Cancer Prediction
- High Grade Prostatic Epithelial Neoplasia
- High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ
- High-risk Oral Precancerous Diseases
- IARC Carcinogens
- Lung Cancer
- Lung; Node
- Melanocytic Lesion, Adult
- Nephrogenic Rests
- Non Alcoholic Steatohepatitis
- Non-Alcoholic Fatty Liver Disease
- Osteochondroma
- Pancreatic Precursor Lesions
- Serous Tubal Intraepithelial Carcinoma
- Smoking History
- Spitz Nevus
- Vulvar Intraepithelial Neoplasia
Interventions
- Samples Other
Other
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 24, 2023
- Primary completion
- Mar 24, 2027
- Completion
- Mar 24, 2032
- Last update posted
- Aug 6, 2025
2023 – 2032
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05463796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05463796 live on ClinicalTrials.gov.